The Worldwide Clinical Trials metabolic team recently connected with sites, sponsors, and colleagues at the American Diabetes Association’s (ADA) 2026 Scientific Sessions. Throughout our conversations, a few themes kept surfacing: how the work itself is changing, what questions trials are now expected to answer, and what it takes to run them well.
Obesity Trials Must Answer More Than Weight Loss
For years, an obesity trial could succeed on a single outcome. Weight came down, the endpoint was met, and the program moved forward. GLP-1 mechanisms settled that question. Significant weight reduction is now achievable, making it difficult for new entrants that focus solely on weight loss to stand out.
To answer this shift, sponsors are designing for broader perspectives. Obesity affects inflammation, hormone signaling, energy metabolism, and organ function. At ADA, we saw how trials are starting to measure across those systems. Body composition also matters, because losing muscle alongside fat is a different result than preserving it. We’re now seeing liver fat, glycemic markers, and cardiovascular signals showing up earlier in development rather than being saved for separate studies later. Even bone mineral density, which rarely came up a year ago, was mentioned in a few conversations.
These are design decisions, and they are cheaper to make early. Adding an endpoint during feasibility is straightforward. Building it back into a late-stage trial after the fact is not.
To learn more about what this shift means for endpoint strategy and trial operations, read our new white paper: Whole-Body Obesity: The Shift from Weight Loss to Systemic Benefit
A Resurgence in Type 1 Diabetes Research
For a while, type 1 diabetes (T1D) research had gone quiet. New scientific developments are changing that. Beta-cell regeneration and immune-pathway work are back on the table, and gut-brain mechanisms are drawing fresh interest — often tested in combination. After years where obesity and type 2 diabetes took most of the attention, it was good to see T1D back in the conversation at ADA.
For sponsors, the resurgence puts a premium on sites that have kept their T1D experience current and know how to run trials built on newer mechanisms.
Enrollment & Retention Depend on the Patient & Site Relationship
This was the throughline ADA 2026. Talking with sites, our team kept hearing the same thing: many metabolic diseases are silent. Patients often do not feel sick, and some do not consider themselves to have a disease at all, which is why retention rests on the relationship between a patient and their site. A recruitment campaign can fill a slot. The relationship is what keeps someone in the study.
We have watched the same shift play out in study design. Enrollment used to be judged on speed, and a short enrollment window was treated as a sign of a healthy study. The cost tended to show up in dropout and messy data later. Sponsors are now choosing and rewarding sites for how well they keep patients in a study and data clean, not just how quickly they enroll patients. The race to fill slots has cooled, and studies are healthier for it.
The sites that do this well treat patient relationships as the real retention tool. Managing expectations honestly and building genuine trust keeps people in a study more reliably than any other single tactic.
The Real Role of Digital Tools in Early Phase Obesity Work
When it comes to bringing CGM, ePRO, and digital biomarkers into early phase obesity trials, not every digital tool earns its place. Wearables, which a few years ago looked like they would be in every protocol, have become less central, partly because they produce a lot of data that are hard to tie back to a clinical question.
The tools that do earn a place are the ones attached to a real endpoint. Continuous glucose monitoring gives a steady read where a handful of fasting draws used to be the only signal. ePRO captures the patient’s own experience in a structured way. Our team presented a poster at ADA on this topic, highlighting the discipline of choice. The best results come from matching the right tool to a clear question, then backing it with good site training and a patient who understands why they are wearing it.
Global Research Runs on Site Partnership & the Patient Voice
A point that came up on the first day stuck with our team. The best trials bring sites into the strategy early because sites know what patients need and what it actually takes to run a protocol on the ground. The patient voice belongs there, too. Understanding what it is like to live with diabetes or a metabolic disease shapes better study design from the start.
Study success is an equation that balances the patient, the site, the CRO, and the sponsor at once. Miss any one of them and the trial feels it. As metabolic studies grow larger and reach across more regions, that balance gets harder to hold — and more valuable when you do. That’s why when we think about consistency across countries, partnership is just as critical as process.
What Comes Next
The science in metabolic disease is widening, and the way trials are designed and run is catching up to it. Obesity programs are measuring more of the body. T1D is active again. Across all of it, the operational answer keeps landing in the same place. Listen to sites, design around the patient, and the data tend to follow.
If you are planning a metabolic program and want to discuss how these themes may impact your work, get in touch today.
This piece draws on our team’s conversations and observations at ADA 2026. For more on the move beyond weight loss, read our white paper, Whole-Body Obesity: The Shift from Weight Loss to Systemic Benefit.
